This company has been marked as potentially delisted and may not be actively trading. Flexion Therapeutics (FLXN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsSustainabilityTrendsBuy This Stock FLXN vs. MOR, GMTX, CALT, ZYME, MENS, SBTX, MBX, AVTE, NLTX, and CYBNShould you be buying Flexion Therapeutics stock or one of its competitors? The main competitors of Flexion Therapeutics include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). Flexion Therapeutics vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Jyong Biotech Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin Flexion Therapeutics (NASDAQ:FLXN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends. Is FLXN or MOR more profitable? Flexion Therapeutics has a net margin of -100.32% compared to MorphoSys' net margin of -226.79%. Flexion Therapeutics' return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Flexion Therapeutics-100.32% N/A -44.26% MorphoSys -226.79%-694.31%-22.55% Does the media prefer FLXN or MOR? In the previous week, Flexion Therapeutics' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score. Company Overall Sentiment Flexion Therapeutics Neutral MorphoSys Neutral Which has more risk & volatility, FLXN or MOR? Flexion Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Which has better valuation and earnings, FLXN or MOR? Flexion Therapeutics has higher earnings, but lower revenue than MorphoSys. Flexion Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlexion Therapeutics$85.55M14.80-$113.71M-$2.01-12.52MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Do insiders and institutionals believe in FLXN or MOR? 90.0% of Flexion Therapeutics shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 9.1% of Flexion Therapeutics shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryFlexion Therapeutics beats MorphoSys on 8 of the 11 factors compared between the two stocks. Get Flexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLXN vs. The Competition Export to ExcelMetricFlexion TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$781.80M$5.73B$9.53BDividend YieldN/A4.84%4.69%4.01%P/E Ratio-12.521.4128.4120.07Price / Sales14.8024.88392.1370.37Price / CashN/A19.5636.1858.54Price / Book-74.016.928.655.87Net Income-$113.71M-$4.13M$3.25B$258.89M Flexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLXNFlexion TherapeuticsN/A$25.16+0.1%N/AN/A$1.27B$85.55M-12.52257MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.38+2.8%N/A+38.0%$2.57BN/A-59.3830High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.4807 of 5 stars$14.32flat$21.00+46.6%+24.0%$997.86M$93.38M-9.55460Upcoming EarningsMENSJyong BiotechN/A$10.06-8.5%N/AN/A$836.30MN/A0.0031News CoverageQuiet Period ExpirationSBTXSilverback TherapeuticsN/A$17.85-0.4%N/A+62.8%$643.64MN/A-7.3883High Trading VolumeMBXMBX Biosciences2.2503 of 5 stars$11.70-4.0%$37.57+221.1%N/A$391.06MN/A0.0036News CoveragePositive NewsAVTEAerovate TherapeuticsN/A$8.69-8.2%N/A-88.2%$251.88MN/A-2.9120High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.34-1.2%N/A-46.8%$209.95MN/A-7.1890High Trading VolumeCYBNCybin2.6317 of 5 stars$7.73-3.7%$85.00+999.6%N/A$177.98MN/A-1.7650 Related Companies and Tools Related Companies MOR Alternatives GMTX Alternatives CALT Alternatives ZYME Alternatives MENS Alternatives SBTX Alternatives MBX Alternatives AVTE Alternatives NLTX Alternatives CYBN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLXN) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flexion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
